The world’s first Covid-19 Human Challenge Trial: The regulatory challenges – TOPRA presentation

VP of Regulatory Affairs, Bruno Speder from hVIVO, part of Open Orphan plc, presents at TOPRA’s webinar on 16 November 2021. Bruno discusses the regulatory aspects of the worlds first COVID-19 characterisation study, run by hVIVO as part of the UK Government’s Human Challenge Programme.

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data). 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Open Orphan Plc

More articles like this

Open Orphan Plc

Understanding Asthma

We have all heard of asthma. You may have asthma, you may have a friend or a loved one with asthma, or you may just be aware of it as the most common respiratory disease in the UK.

Open Orphan Plc

Open Orphan’s hVIVO wins £5.1m RSV human challenge study deal

Specialist pharmaceutical services clinical research company Open Orphan said its hVIVO subsidiary has signed a £5.1m contract with a biopharmaceutical company to use its respiratory syncytial virus (RSV) human challenge study model. The study is due to start

Open Orphan Plc

Open Orphan’s hVIVO signs £5.1m RSV Human Challenge Study contract

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation and world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that hVIVO , a subsidiary of Open Orphan, has signed a £5.1m contract with a biopharmaceutical

Open Orphan Plc

Open Orphan subsidiary renews million-euro deal

Venn Life Sciences, a subsidiary of Irish-led vaccine research firm Open Orphan, has signed a million-euro contract renewal with an unnamed global pharmaceutical client. The contract – worth worth £1.5m (around €1.7m) over two years – will commence

Open Orphan Plc

Open Orphan’s Venn Life Sciences signs contract renewal worth £1.5m

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation and world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that Venn Life Sciences, a subsidiary of Open Orphan, has signed a contract renewal